Imvaria key facts
as of Oct 2026- Developer of an AI-driven diagnostic software designed for noninvasive assessment of lung diseases.
- Imvaria is valued at approximately $11.0M as of Oct 2026 (last reported valuation).
- It has raised $3.0M; the latest was Later Stage VC in Jan 2026.
- Notable investors include MedTech Innovator, National Institutes of Health, StartX (US), Endless Frontier Labs, Kevin Moore — 13 tracked in total.
- Status: Privately Held (backing).
Imvaria's last reported valuation, Apr 2020. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Imvaria: the Monday email on marks, rounds and moves
Imvaria funding rounds
No funding rounds for Imvaria are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Imvaria
13+Imvaria valuation
Imvaria's last reported valuation was $11 million in Apr 2020. No priced round, secondary trade or fund mark has surfaced since.
Imvaria investors
13 investors are on record for Imvaria, including MedTech Innovator, National Institutes of Health, StartX (US) and Endless Frontier Labs.
About Imvaria
Developer of an AI-driven diagnostic software designed for noninvasive assessment of lung diseases. The company's software analyzes clinical imaging and lab data through a centralized, cloud-based lab system that processes cases across various data types and laboratory results to improve disease detection and reduce diagnostic delays, enabling healthcare providers and pulmonologists to gain earlier and accurate insights into complex conditions like interstitial lung diseases without the need for invasive procedures.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2019
- Employees
- 15
- Website
- imvaria.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.